Results 211 to 220 of about 109,968 (264)

Infectious Complications Following CD30 Chimeric Antigen Receptor T-cell Therapy in Adults. [PDF]

Open Forum Infect Dis
Cao F, Xiu Y, Mohnasky M, Serody JS, Armistead P, Dotti G, Smith M, Huggins J, Messina J, Ramachandran B, Saullo J, Stromberg J, Saha MK, Walsh M, Savoldo B, Grover N, Henderson HI, Andermann TM.   +17 more
europepmc   +1 more source

Mapping the Radiopharmaceutical Therapy Landscape for Prostate Cancer: Insights Into Global Clinical Trial Trends and Future Directions

Med Research, EarlyView.
Zhiwu Dong, Sixiang Yan, Xiaodong Liu, Peng Gu   +3 more
wiley   +1 more source

Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies? [PDF]

J Hematol Oncol
Vo MC, Tran VD, Nguyen VT, Ruzimurodov N, Trung DT, Kim SK, Jung SH, Lee JJ.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Advances in chimeric antigen receptor T cells

Current Opinion in Hematology, 2020
Purpose of review To discuss the important advances in CAR T cell therapy over the past year, focusing on clinical results where available. Recent findings Approximately 30 years after they were first conceived of and 15 years after the first small-scale single-center clinical ...
Ofrat, Beyar-Katz, Saar, Gill
openaire   +2 more sources

Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas

Hematology/Oncology Clinics of North America, 2023
The authors review the current use of chimeric antigen receptor (CAR)-transduced T cells (CAR-T) in Hodgkin lymphoma (HL) and T-cell lymphomas (TCL) and discuss the data on CD30-targeting CAR-T cells, which seem to be safe and effective in HL. In addition, the authors examine the use of CAR-T cells targeting CD30, CD5, or CD7 in TCL, while highlighting
Muhsen, Ibrahim N, Hill, LaQuisa C, Ramos, Carlos A   +2 more
openaire   +3 more sources

Chimeric antigen receptor T-cell toxicity

Current Opinion in Pediatrics, 2019
Purpose of review Chimeric antigen receptor -(CAR) T-cell therapy has become a commonly used immunotherapy originally used in the treatment of B-cell leukemias but which are now applied broadly across tumor classes. Although high rates of remission are associated with CAR T-cell therapy, toxicities associated with these novel ...
DaMarcus E, Baymon, Edward W, Boyer
openaire   +2 more sources

Chimeric antigen receptor T cells march into T cell malignancies

Journal of Cancer Research and Clinical Oncology, 2023
T cell malignancies represent a diverse collection of leukemia/lymphoma conditions in humans arising from aberrant T cells. Such malignancies are often associated with poor clinical prognoses, cancer relapse, as well as progressive resistance to anti-cancer treatments.
Jie, Tang, Xudong, Zhao
openaire   +2 more sources

Biomaterials for chimeric antigen receptor T cell engineering

Acta Biomaterialia, 2023
Chimeric antigen receptor T (CAR-T) cells have achieved breakthrough efficacies against hematological malignancies, but their unsatisfactory efficacies in solid tumors limit their applications. The prohibitively high prices further restrict their access to broader populations.
Huanqing, Niu, Penghui, Zhao, Wujin, Sun
openaire   +2 more sources